Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous …

Background Corticosteroids are routinely utilized to alleviate edema in patients with
intracranial lesions and are first-line agents to combat immune-related adverse events …

Contemporary paediatric clinical trials have improved 5-year event-free survival above 85%
and 5-year overall survival above 90% in B-cell acute lymphoblastic leukaemia (ALL) in …

Purpose Survival for children and young adults with high-risk B-acute lymphoblastic
leukemia has improved significantly, but 20% to 25% of patients are not cured. Children's …

Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. It
has an overall survival of approximately 80%, with certain subsets experiencing greater than …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
Advancements in technology that enhance our understanding of the biology of the disease …

T-cell acute lymphoblastic leukemia (T-ALL) is biologically distinct from its B lymphoblastic
(B-ALL) counterpart and shows different kinetic patterns of disease response. Although very …

As immune-based therapies for cancer become potent, more effective, and more widely
available, optimal management of their unique toxicities becomes increasingly important …

Background Minimal residual disease (MRD) is the most sensitive and specific predictor of
relapse risk in children with acute lymphoblastic leukaemia (ALL) during remission. We …